Immunodeficiency clinical trials
17 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
- Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
- R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
- Detection and Characterization of Host Defense Defects
- Apheresis of Patients With Immunodeficiency
- Allergy and Immunology Natural History Study
- Biologics And Clinical Immunology Cohort at Sinai
- Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
- Umbilical Cord Blood Transplantation From Unrelated Donors
- Natural History of Noncirrhotic Portal Hypertension
- The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
- Evaluation of Patients With Immune Function Abnormalities
- Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
- Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Immunodeficiency” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.